Media stories about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.2806665488898 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
A number of research firms have weighed in on AVEO. FBR & Co restated a “buy” rating and set a $3.00 price objective on shares of AVEO Pharmaceuticals in a research note on Friday, June 30th. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Monday, July 24th. Piper Jaffray Companies lifted their price target on shares of AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, August 28th. Finally, Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $3.42.
Shares of AVEO Pharmaceuticals (NASDAQ AVEO) traded up 9.56% during mid-day trading on Friday, reaching $2.98. 2,442,330 shares of the company traded hands. The firm has a 50-day moving average price of $3.56 and a 200 day moving average price of $2.19. The firm’s market capitalization is $352.55 million. AVEO Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $4.24.
WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/27/aveo-pharmaceuticals-aveo-earning-somewhat-positive-press-coverage-study-shows.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.